ATS Corporation Q3 2026 Earnings Call Summary

1Key Financial Results and Metrics

Order Bookings: $821 million, up nearly 12% sequentially but down 7% year-over-year due to lower run rates in Transportation and fewer large enterprise bookings compared to the previous year.

Revenues: $761 million, a 16.7% increase from Q3 2025, driven by organic growth of 12.6% and a 4.1% benefit from foreign exchange.

Adjusted Earnings from Operations: $79.9 million, a 21.6% increase year-over-year.

Gross Margin: 29.6%, down 111 basis points from the previous year, attributed to program mix.

Earnings Per Share (EPS): $0.48 on an adjusted basis.

Order Backlog: Approximately $2.1 billion, reflecting a healthy mix across end markets and geographies.

2Strategic Updates and Business Highlights

Leadership Changes: Doug Wright joined as CEO, emphasizing execution discipline, margin performance, and capital allocation. Ryan McLeod transitioned to a new role, with Anne Cybulski serving as interim CFO.

New Appointments: Sarah Moore appointed as Life Sciences Group Executive and Simon Roberts to lead Packaging & Food Technology.

Service Integration: The growing Services business has been embedded within operating units to enhance accountability and customer alignment.

Market Performance: Strong demand in Life Sciences, particularly in radiopharmaceuticals and GLP-1 auto-injectors. Energy sector saw a record backlog driven by refurbishment projects.

3Forward Guidance and Outlook

Q4 Revenue Guidance: Expected to be between $710 million and $750 million.

CapEx Investment: Projected to be between $70 million and $90 million for fiscal 2026, slightly lower than previous estimates.

Long-Term Focus: Continued emphasis on margin expansion, capital efficiency, and leveraging opportunities in high-growth sectors.

4Bad News, Challenges, or Points of Concern

Decline in Bookings: Year-over-year decline in bookings raises concerns about future revenue growth, particularly in Transportation.

Gross Margin Pressure: The decrease in gross margin indicates challenges in program execution and mix, necessitating further focus on operational efficiencies.

Restructuring Costs: Increased restructuring costs of $20 million may impact short-term profitability, although intended for long-term efficiency gains.

Market Volatility: Ongoing geopolitical and trade uncertainties could affect operations and customer demand.

5Notable Q&A Insights

CEO's Focus: Doug Wright highlighted priorities in the first 90 days, including improving margin expansion and capital allocation discipline.

Energy Sector Growth: Significant growth in the Energy sector driven by refurbishment projects, with ongoing participation in new builds.

Life Sciences Outlook: Continued strong demand in Life Sciences, with a focus on diversifying the pipeline beyond GLP-1 therapies.

Transportation Strategy: Acknowledgment of the need for a more cautious approach in the Transportation sector, focusing on niche opportunities rather than large-scale projects.

Capital Deployment: Emphasis on disciplined capital allocation, with potential for increased M&A activity as leverage ratios improve. Overall, ATS demonstrated solid financial performance in Q3 2026, with strategic initiatives aimed at enhancing operational efficiency and market position, despite facing some challenges in bookings and margin pressures.